Wnt5a: A player in the pathogenesis of atherosclerosis and other inflammatory disorders

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 155-162

  Bhatt, Pooja M ^a,c   Malgor, Ramiro ^a,b  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Inflammatory disorders; Macrophages; Wnt5a

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN; WNT5A PROTEIN; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LRP5 PROTEIN, HUMAN; LRP6 PROTEIN, HUMAN; ONCOPROTEIN; WNT PROTEIN; WNT5A PROTEIN, HUMAN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW DERIVED MACROPHAGE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; HUMAN; INFLAMMATORY DISEASE; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; WNT SIGNALING PATHWAY; ANIMAL; CELL DIFFERENTIATION; CELL LINEAGE; INFLAMMATION; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOMARKERS; CELL DIFFERENTIATION; CELL LINEAGE; HUMANS; INFLAMMATION; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MACROPHAGES; MICE; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84934877428     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.027     Document Type: Review

References (71)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
2. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004, 20:781-810.
3. Angers S., Moon R.T. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009, 10:468-477.
4. Li C., Chen H., Hu L., Xing Y., Sasaki T., Villosis M.F., et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 2008, 9:11.
5. Gavin B.J., McMahon J.A., McMahon A.P. Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse development. Genes Dev 1990, 4:2319-2332.
6. Nusse R., Varmus H.E. Wnt genes. Cell 1992, 69:1073-1087.
7. Sen M., Lauterbach K., El-Gabalawy H., Firestein G.S., Corr M., Carson D.A. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A 2000, 97:2791-2796.
8. Blumenthal A., Ehlers S., Lauber J., Buer J., Lange C., Goldmann T., et al. The wingless homolog WNT5A and its receptor frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006, 108:965-973.
9. Christman M.A., Goetz D.J., Dickerson E., McCall K.D., Lewis C.J., Benencia F., et al. Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2008, 294:H2864-H2870.
10. Pereira C.P., Bachli E.B., Schoedon G. The Wnt pathway: a macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep 2009, 11:236-242.
11. Bhatt P.M., Lewis C.J., House D.L., Keller C.M., Kohn L.D., Silver M.J., et al. Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages. Open Circ Vasc J 2012, 5:1-7.
12. Mikels A.J., Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006, 25:7461-7468.
13. Hsieh J.C., Kodjabachian L., Rebbert M.L., Rattner A., Smallwood P.M., Samos C.H., et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999, 398:431-436.
14. Veeman M.T., Axelrod J.D., Moon R.T. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003, 5:367-377.
15. McDonald S.L., Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer 2009, 101:209-214.
16. McCall K.D., Harii N., Lewis C.J., Malgor R., Kim W.B., Saji M., et al. High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 2007, 148:4226-4237.
17. Kilian B., Mansukoski H., Barbosa F.C., Ulrich F., Tada M., Heisenberg C.P. The role of Ppt/Wnt5 in regulating cell shape and movement during zebrafish gastrulation. Mech Dev 2003, 120:467-476.
18. Kuhl M., Sheldahl L.C., Park M., Miller J.R., Moon R.T. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000, 16:279-283.
19. Kohn A.D., Moon R.T. Wnt and calcium signaling: beta-catenin-independent pathways. Cell calcium 2005, 38:439-446.
20. Kuhl M., Geis K., Sheldahl L.C., Pukrop T., Moon R.T., Wedlich D. Antagonistic regulation of convergent extension movements in Xenopus by Wnt/beta-catenin and Wnt/Ca2+ signaling. Mech Dev 2001, 106:61-76.
21. Seifert J.R., Mlodzik M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 2007, 8:126-138.
22. Katoh M., Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and notch signaling cascades. Int J Mol Med 2009, 23:763-769.
23. Kikuchi A., Yamamoto H., Sato A., Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol 2012, 204:17-33.
24. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997, 11:3286-3305.
25. Smolich B.D., McMahon J.A., McMahon A.P., Papkoff J. Wnt family proteins are secreted and associated with the cell surface. Mol Biol Cell 1993, 4:1267-1275.
26. Oishi I., Suzuki H., Onishi N., Takada R., Kani S., Ohkawara B., et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 2003, 8:645-654.
27. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006, 4:570-582.
28. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
29. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
30. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
31. Wright M., Aikawa M., Szeto W., Papkoff J. Identification of a Wnt-responsive signal transduction pathway in primary endothelial cells. Biochem Biophys Res Co 1999, 263:384-388.
32. Libby P. Inflammation in atherosclerosis. Nature 2002, 868-874.
33. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
34. Masckauchan T.N., Agalliu D., Vorontchikhina M., Ahn A., Parmalee N.L., Li C.M., et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell 2006, 17:5163-5172.
35. Cheng C.W., Yeh J.C., Fan T.P., Smith S.K., Charnock-Jones D.S. Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration. Biochem Biophys Res Co 2008, 365:285-290.
36. Malgor R., Bhatt P.M., Connolly B.A., Jacoby D.L., Feldmann K.J., Silver M.J., et al. Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflam Res 2014, 63:277-285.
37. Qin L., Hu R., Zhu N., Yao H.L., Lei X.Y., Li S.X., et al. The novel role and underlying mechanism of Wnt5a in regulating cellular cholesterol accumulation. Clin Exp Pharmacol Physiol 2014, [Epub ahead of print]. 10.1111/1440-1681.12258.
38. Szymanski C., Noriko Kantake N., Kelly McCall K., Malgor R. Expression of Wnt5a and its effect on oxLDL uptake in THP-1 cells. FASEB J 2014, LB534.
39. Kim J., Kim J., Kim D.W., Ha Y., Ihm M.H., Kim H., et al. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 2010, 185:1274-1282.
40. Mill C., George S.J. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res 2012, 95:233-240.
41. Doherty T.M., Asotra K., Fitzpatrick L.A., Qiao J.-H., Wilkin D.J., Detrano R.C., et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U S A 2003, 100(20):11201-11206.
42. Xin H., Xin F., Zhou S., Guan S. The Wnt5a/Ror2 pathway is associated with determination of the differentiation fate of bone marrow mesenchymal stem cells in vascular calcification. Int J Mol Med 2013, 31(3):583-588.
43. Woldt E., Terrand J., Mlih M., Matz R.L., Bruban V., Coudane F., et al. The nuclear hormone receptor PPARgamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun 2012, 3:1077.
44. Fujiwara N., Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:281-286.
45. Gui T., Shimokado A., Sun Y., Akasaka T., Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediat Inflamm 2012, 2012:693083.
46. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
47. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol;7:77-86.
48. Gordon S. Alternative activation of macrophages. Nat Immunol 2003, 3:23-35.
49. Bergenfelz C., Medrek C., Ekstrom E., Jirstrom K., Janols H., Wullt M., et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol 2012, 188:5448-5458.
50. Sen M., Chamorro M., Reifert J., Corr M., Carson D.A. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001, 44:772-781.
51. Ghosh M.C., Collins G.D., Vandanmagsar B., Patel K., Brill M., Carter A., et al. Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. Blood 2009, 114:1366-1373.
52. Katoh M., Katoh M. STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer. Int J Mol Med 2007, 19:273-278.
53. Pereira C., Schaer D.J., Bachli E.B., Kurrer M.O., Schoedon G. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008, 28(3):504-510.
54. Fujio Y., Matsuda T., Oshima Y., Maeda M., Mohri T., Ito T., et al. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett 2004, 573:202-206.
55. Schaale K., Neumann J., Schneider D., Ehlers S., Reiling N. Wnt signaling in macrophages: augmenting and inhibiting mycobacteria-induced inflammatory responses. Eur J Cell Biol 2011, 90:553-559.
56. Pukrop T., Klemm F., Hagemann T., Gradl D., Schulz M., Siemes S., et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A 2006, 103:5454-5459.
57. Kim J., Chang W., Jung Y., Song K., Lee I. Wnt5a activates THP-1 monocytic cells via a beta-catenin-independent pathway involving JNK and NF-kappaB activation. Cytokine 2012, 60:242-248.
58. Yang L., Chu Y., Wang Y., Zhao X., Xu W., Zhang P., et al. siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-kappaB pathways. Int J Mol Med 2014 Jul 22, 10.3892/ijmm.2014.1890.
59. Karouzakis E., Neidhart M., Gay R.E., Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett 2006, 106:8-13.
60. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442.
61. Sen M., Carson D.A. Wnt signaling in rheumatoid synoviocyte activation. Mod Rheumatol 2002, 12:5-9.
62. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
63. Reischl J., Schwenke S., Beekman J.M., Mrowietz U., Sturzebecher S., Heubach J.F. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127:163-169.
64. Romanowska M., Evans A., Kellock D., Bray S.E., McLean K., Donandt S., et al. Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferon. PloS One 2009, 4:e5354.
65. Bilkovski R., Schulte D.M., Oberhauser F., Mauer J., Hampel B., Gutschow C., et al. Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via Wnt-5a in humans. Int J Obes 2011, 35:1450-1454.
66. Terrand J., Bruban V., Zhou L., Gong W., El Asmar Z., May P., et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J Biol Chem 2009, 284(1):381-388.
67. Kummitha C.M., Mayle K.M., Christman M.A., Deosarkar S.P., Schwartz A.L., McCall K.D., et al. A sandwich ELISA for the detection of Wnt5a. J Immunol Methods 2010, 352:38-44.
68. Kadl A., Meher A.K., Sharma P.R., Lee M.Y., Doran A.C., Johnstone S.R., et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 2010, 107:737-746.
69. van Tits L.J., Stienstra R., van Lent P.L., Netea M.G., Joosten L.A., Stalenhoef A.F. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011, 214:345-349.
70. Mantovani A., Garlanda C., Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009, 29:1419-1423.
71. Hirose K., Iwabuchi K., Shimada K., Kiyanagi T., Iwahara C., Nakayama H., et al. Different responses to oxidized low-density lipoproteins in human polarized macrophages. Lipids Health Dis 2011, 10:1.